Global Markets Direct’s, 'Postoperative Ileus - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Postoperative Ileus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Postoperative Ileus. Postoperative Ileus - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Postoperative Ileus. - A review of the Postoperative Ileus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Postoperative Ileus pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Postoperative Ileus. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Postoperative Ileus pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Postoperative Ileus - Pipeline Review, H1 2013 Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Postoperative Ileus Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Postoperative Ileus 7 Postoperative Ileus Therapeutics under Development by Companies 9 Mid Clinical Stage Products 10 Comparative Analysis 10 Discovery and Pre-Clinical Stage Products 11 Comparative Analysis 11 Postoperative Ileus Therapeutics - Products under Development by Companies 12 Companies Involved in Postoperative Ileus Therapeutics Development 13 LG Life Sciences, Ltd 13 Helsinn Healthcare S.A. 14 Botanic Century 15 RaQualia Pharma Inc. 16 Postoperative Ileus - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Drug Profiles 22 RQ-00201894 - Drug Profile 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 Melokinex - Drug Profile 23 Product Description 23 Mechanism of Action 23 RandD Progress 23 ipamorelin - Drug Profile 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 LD02GIFRO - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 Drug For Bowel Motility Disorders - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 Postoperative Ileus Therapeutics - Drug Profile Updates 27 Postoperative Ileus Therapeutics - Discontinued Products 28 Postoperative Ileus Therapeutics - Dormant Products 29 Postoperative Ileus - Product Development Milestones 30 Featured News and Press Releases 30 Sep 14, 2012: RaQualia Pharma's Motilin Receptor Agonist RQ-00201894 Advances To Pre-clinical Stage 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 32 Disclaimer 32
List of Tables
Number of Products Under Development for Postoperative Ileus, H1 2013 7 Products under Development for Postoperative Ileus - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Comparative Analysis by Mid Clinical Stage Development, H1 2013 10 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 11 Products under Development by Companies, H1 2013 12 LG Life Sciences, Ltd, H1 2013 13 Helsinn Healthcare S.A., H1 2013 14 Botanic Century, H1 2013 15 RaQualia Pharma Inc., H1 2013 16 Assessment by Monotherapy Products, H1 2013 17 Assessment by Stage and Route of Administration, H1 2013 19 Assessment by Stage and Molecule Type, H1 2013 21 Postoperative Ileus Therapeutics - Drug Profile Updates 27 Postoperative Ileus Therapeutics - Discontinued Products 28 Postoperative Ileus Therapeutics - Dormant Products 29
List of Figures
Number of Products under Development for Postoperative Ileus, H1 2013 7 Products under Development for Postoperative Ileus - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Mid Clinical Stage Products, H1 2013 10 Discovery and Pre-Clinical Stage Products, H1 2013 11 Assessment by Monotherapy Products, H1 2013 17 Assessment by Route of Administration, H1 2013 18 Assessment by Stage and Route of Administration, H1 2013 19 Assessment by Molecule Type, H1 2013 20 Assessment by Stage and Molecule Type, H1 2013 21